Cancer therapy using beta glucan and antibodies

• US 8,883,760 B2
• Filed: 09/04/2003
• Issued: 11/11/2014
• Est. Priority Date: 09/04/2002
• Status: Active Grant

• Current Assignee: University of Louisville, University of Louisville Research Foundation
• Original Assignee: University of Louisville
• Inventors: Ross, Gordon D.
• Primary Examiner(s): RICCI, CRAIG D
• Application Number:
  US10/526,185
• Publication Number:
  US 20060009419A1
• Time in Patent Office: 4,086 Days
• Field of Search: None
• US Class Current: 514/54
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/545 characterised by the dose, timing or administration schedule
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/47 Quinolines; Isoquinolines
• CPC Class Codes: A61K 31/715 Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
• CPC Class Codes: A61K 31/716 Glucans
• CPC Class Codes: A61K 39/39558 against tumor tissues, cells, antigens
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/04 specific for metastasis
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/04 Immunostimulants
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2317/732 Antibody-dependent cellular cytotoxicity [ADCC]
• CPC Class Codes: C07K 2317/75 Agonist effect on antigen
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Abstract

The present invention relates to methods of using neutral soluble glucan and monoclonal antibodies for antitumor therapy. Neutral soluble Beta (1,3; 1,6) glucan (NSG) enhances the tumoricidal activity of the innate immune system by binding to the C3 complement protein receptor CR3. The glucan does not stimulate the induction of inflammatory cytokines. Also described are methods of using whole glucan particles (WGP) as an immunomodulator by inducing a shift from a Th2 response to the Th1 response, leading to an enhanced antitumor cytotoxic T-cell response.

Claims

1. A method of suppressing or eliminating mammary carcinoma stably expressing trastuzumab-specific antigen, comprising administering a yeast neutral soluble glucan and trastuzumab to a subject having mammary carcinoma stably expressing trastuzumab-specific antigen, wherein the glucan does not induce systemic release of inflammatory cytokines, and the glucan and trastuzumab together synergistically suppress or eliminate mammary carcinoma stably expressing trastuzumab-specific antigen.

2. The method of claim 1, wherein the yeast neutral soluble glucan is in a single helix conformation, a triple helix conformation, or a combination thereof.

3. The method of claim 1, wherein the yeast neutral soluble beta glucan is administered parenterally.